Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive”

Company Overview - Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) specializes in developing oral drugs for rare hormonal diseases and tumors, with its lead candidate, Paltusotine, currently in Phase 3 trials for acromegaly and carcinoid syndrome [2] - The company's portfolio also includes treatments for conditions such as Cushing's disease and obesity [2] Investment Insights - Jim Cramer highlighted CRNX as a stock to consider, noting that Goldman Sachs has issued a Buy recommendation, indicating a positive outlook from a major financial firm [1] - Cramer emphasized that CRNX, priced at $55, is a more substantial investment compared to lower-priced stocks, suggesting that investors should focus on the company's fundamentals rather than just the stock price [1]